PPCH is preparing to intiate Phase I human trials
Post# of 377
Posted On: 12/19/2015 9:57:50 AM
PPCH is preparing to intiate Phase I human trials in the coming year. The recent financial inflow of over 4 MLL dollars willl propel research well into 2016.
" Propanc Health Group Corporation (PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from pancreatic and colorectal cancers, today announced the Company has secured $4 million from an institutional investor in order to progress their lead product, PRP, towards human trials.
Under the terms of the Agreement, a $1.2 million promissory note entered into by the investor on September 24th has now been included in the investment amount under the new purchase agreement. A further $2.8 million of the investment amount will be paid (totaling $4 million), pending the achievement of certain milestones and equity conditions set forth in the agreement.
The aggregate deal size provides sufficient capital to cover future research and development activities leading up to the preparation and commencement of human trials for their lead product, PRP, and is expected to sufficiently cover the Company's operations over the next 12 months" NOV 10, 2015
" Propanc Health Group Corporation (PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from pancreatic and colorectal cancers, today announced the Company has secured $4 million from an institutional investor in order to progress their lead product, PRP, towards human trials. Under the terms of the Agreement, a $1.2 million promissory note entered into by the investor on September 24th has now been included in the investment amount under the new purchase agreement. A further $2.8 million of the investment amount will be paid (totaling $4 million), pending the achievement of certain milestones and equity conditions set forth in the agreement.
The aggregate deal size provides sufficient capital to cover future research and development activities leading up to the preparation and commencement of human trials for their lead product, PRP, and is expected to sufficiently cover the Company's operations over the next 12 months" NOV 10, 2015
(0)
(0)